NASDAQ:NAMS NewAmsterdam Pharma Q2 2023 Earnings Report $16.24 +0.21 (+1.28%) As of 02:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast NewAmsterdam Pharma EPS ResultsActual EPSN/AConsensus EPS -$0.45Beat/MissN/AOne Year Ago EPSN/ANewAmsterdam Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANewAmsterdam Pharma Announcement DetailsQuarterQ2 2023Date8/7/2023TimeN/AConference Call DateMonday, August 7, 2023Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Remove Ads Earnings DocumentsPress Release(8-K) NewAmsterdam Pharma Earnings HeadlinesNewAmsterdam Pharma (NAMS): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside PotentialApril 11, 2025 | msn.comBrokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.33April 10, 2025 | americanbankingnews.comGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.April 17, 2025 | Weiss Ratings (Ad)NewAmsterdam Pharma Company (NAMS) Receives a Buy from TD CowenApril 9, 2025 | markets.businessinsider.comNewAmsterdam Pharma Company (NAMS) Gets a Buy from NeedhamApril 9, 2025 | markets.businessinsider.com4NAMS : The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 ExpertsApril 8, 2025 | benzinga.comSee More NewAmsterdam Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NewAmsterdam Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NewAmsterdam Pharma and other key companies, straight to your email. Email Address About NewAmsterdam PharmaNewAmsterdam Pharma (NASDAQ:NAMS) Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.View NewAmsterdam Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth Ahead Upcoming Earnings HDFC Bank (4/18/2025)Intuitive Surgical (4/22/2025)Tesla (4/22/2025)Chubb (4/22/2025)Canadian National Railway (4/22/2025)Capital One Financial (4/22/2025)Danaher (4/22/2025)Elevance Health (4/22/2025)General Electric (4/22/2025)Lockheed Martin (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
